About this trial
Periodontitis is a multifactorial disease characterized by chronic inflammation of the gum tissue and alveolar bone destruction, and is known to be associated with various systemic diseases. Hyperuricemia, on the other hand, is a metabolic condition characterized by increased serum uric acid levels and can affect inflammation, oxidative stress, and bone metabolism. In recent years, the relationship between hyperuricemia and periodontal diseases has been increasingly investigated, but the biological mechanisms of this relationship have not yet been fully elucidated. Therefore, this study aimed to determine whether there is a relationship between hyperuricemia and periodontitis and to reveal the possible pathophysiological mechanisms of this relationship, which are shaped by inflammation, oxidative stress, and bone metabolism.
A total of 80 individuals aged 18-65 years will be included in this clinical observational study. The periodontal status of the participants will be assessed using clinical periodontal parameters such as probing pocket depth, clinical attachment loss, plaque index, gingival index, and bleeding on probing. Participants will be divided into four groups according to their periodontal status and the presence of hyperuricemia: individuals with periodontitis and hyperuricemia, individuals with periodontally healthy and hyperuricemia, individuals with periodontitis but without hyperuricemia, and individuals with periodontally healthy and without hyperuricemia. Gingival crevicular fluid and serum samples will be taken from the participants. In these samples, receptor-mediated nuclear factor kappa B ligand, osteoprotegerin, total antioxidant status, total oxidant status, oxidative stress index, interleukin-1 beta, interleukin-10, interleukin-18, and nucleotide-binding oligomerization domain-like receptor protein 3 levels will be analyzed. This study is considered unique because it examines the relationship between hyperuricemia and periodontitis by evaluating inflammation, oxidative stress, and bone metabolism parameters together.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Being between 18 and 65 years of age
Being systemically healthy or diagnosed with hyperuricemia
Having at least 20 natural teeth
Being periodontally healthy or diagnosed with periodontitis
Disqualifiers
Diabetes, cardiovascular disease, osteoporosis, chronic kidney disease, metabolic syndrome, and obesity are systemic diseases that may affect purine metabolism.
Smoking
Pregnancy or lactation
Having received periodontal treatment within the last 3-6 months
Trial population
Recep Tayyip Erdoğan University Faculty of Dentistry
Trial design
Case-control
Prospective
Treatments tested in this trial
Collection of gingival crevicular fluid (GCF) and serum samples
Other interventionSerum and GCF samples will be collected from participants in the first session
Measurement of periodontal clinical parameters
Other interventionPeriodontal clinical parameters will be measured from participants initially
Treatment groups
Trial outcomes
Primary outcomes
Periodontal pocket depth
The distance between the gingival margin and the base of the pocket will be measured in millimeters.
clinical attachment loss
The distance between the enamel-cementum junction and the base of the pocket will be measured in millimeters.
Secondary outcomes
Level of interleukin-1 beta
Interleukin-1 beta levels will be determined from gingival crevicular fluid and serum samples using the ELISA method.
Level of interleukin-10
Interleukin-10 levels will be determined from gingival crevicular fluid and serum samples using the ELISA method.
Level of interleukin-18
Interleukin-18 levels will be determined from gingival crevicular fluid and serum samples using the ELISA method.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.